Literature DB >> 21282587

Bevacizumab antiangiogenic therapy for glioblastoma.

Larry Junck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282587     DOI: 10.1212/WNL.0b013e31820a0d7e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Authors:  Terri S Armstrong; Patrick Y Wen; Mark R Gilbert; David Schiff
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

2.  Outcome of discontinuing bevacizumab prior to malignant glioma progression.

Authors:  Wendy J Sherman; Jeffrey J Raizer; Sean A Grimm
Journal:  J Neurooncol       Date:  2012-10-12       Impact factor: 4.130

3.  Wound healing complications in brain tumor patients on Bevacizumab.

Authors:  Harshad Ladha; Tushar Pawar; Mark R Gilbert; Jacob Mandel; Barbara O-Brien; Charles Conrad; Margaret Fields; Teresa Hanna; Carolyn Loch; Terri S Armstrong
Journal:  J Neurooncol       Date:  2015-08-23       Impact factor: 4.130

4.  Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models.

Authors:  Chandagirikoppal V Kavitha; Chapla Agarwal; Rajesh Agarwal; Gagan Deep
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

5.  Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.

Authors:  Yi Li; Jun Li; Yat Ming Woo; Zan Shen; Hong Yao; Yijun Cai; Marie Chia-Mi Lin; Wai Sang Poon
Journal:  BMC Cancer       Date:  2017-02-13       Impact factor: 4.430

6.  MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma.

Authors:  Caterina Brighi; Lee Reid; Alison L White; Laura A Genovesi; Marija Kojic; Amanda Millar; Zara Bruce; Bryan W Day; Stephen Rose; Andrew K Whittaker; Simon Puttick
Journal:  Neurooncol Adv       Date:  2020-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.